The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Whole-genome landscape of pancreatic neuroendocrine tumours
Abstract
The diagnosis of pancreatic neuroendocrine tumours (PanNETs) is increasing owing to more sensitive detection methods, and this increase is creating challenges for clinical management. We performed whole-genome sequencing of 102 primary PanNETs and defined the genomic events that characterize their pathogenesis. Here we describe the mutational signatures they harbour, including a deficiency in G:C > T:A base excision repair due to inactivation of MUTYH, which encodes a DNA glycosylase. Clinically sporadic PanNETs contain a larger-than-expected proportion of germline mutations, including previously unreported mutations in the DNA repair genes MUTYH, CHEK2 and BRCA2. Together with mutations in MEN1 and VHL, these mutations occur in 17% of patients. Somatic mutations, including point mutations and gene fusions, were commonly found in genes involved in four main pathways: chromatin remodelling, DNA damage repair, activation of mTOR signalling (including previously undescribed EWSR1 gene fusions), and telomere maintenance. In addition, our gene expression analyses identified a subgroup of tumours associated with hypoxia and HIF signalling.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“substitution signatures were dominated by C>A transversions in NpCpA or NpCpT contexts (Figures 2 and 3) previously associated with inactivation of the BER gene MUTYH [11].”
From Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers (2019) · cites this paper as [11]
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citationIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,645
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationMermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. M., Beroukhim, R., & Getz, G. A. (2011) · Genome biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,520
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
ClinVar: public archive of interpretations of clinically relevant variants
Landrum, M. J., Lee, J. M., Benson, M., Brown, G., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Hoover, J., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1222 · Cited by 2,758
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citationMassive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,000
Lin, A. L., Rudneva, V. A., Richards, A. L., Zhang, Y., Woo, H. J., Cohen, M. A., Tisnado, J., Majd, N., Wardlaw, S. L., Page‐Wilson, G., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02736-8 · Cited by 35
“…in corticotroph PitNETs more closely resembles a pattern of LOH found in pancreatic neuroendocrine tumors with a more aggressive phenotype (characterized by loss of chromosomes 1, 2, 3, 6, 8, 10, 11, 16, 21, and 22) [43] and other endocrine neoplasms, such as adrenocortical carcinoma [54].”
BackgroundBoons, G., Vandamme, T., Peeters, M., Beyens, M., Driessen, A. L. C., Janssens, K., Zwaenepoel, K., Roeyen, G., Camp, G. V., & de Beeck, K. O. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00467 · Cited by 34
Trikalinos, N. A., Tan, B. R., Amin, M. A., Liu, J., Govindan, R., & Morgensztern, D. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-0525-6 · Cited by 34
Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs
Shi, M., Fan, Z., Xu, J., Yang, J., Li, Y., Gao, C., Su, P., Wang, X., & Zhan, H. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188637 · Cited by 34
Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumorPreprint
Williamson, L., Steel, M. J., Grewal, J., Thibodeau, M. L., Stutheit-Zhao, E. Y., Loree, J. M., Yang, K., Gorski, S. M., Mungall, A. J. J., Mungall, K., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a003814 · Cited by 34
“Loss-of-function mutations in TSC1 and TSC2 occur in a subset of PanNETs (Jiao et al. 2011; Scarpa et al. 2017).”
InfluentialNutrient sensing of mTORC1 signaling in cancer and aging
Jiang, C., Tan, X., Liu, N., Yan, P., Hou, T., & Wei, W. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.08.001 · Cited by 35
Gosain, R., Ball, S., Rana, N. K., Groman, A. E., Gage‐Bouchard, E. A., Dasari, A. N., & Mukherjee, S. (2019) · Cancer · doi:10.1002/cncr.32607 · Cited by 33
“174 1/2 1592 (29) 14,178 (30) 3/4 88 (2) 661 (1) Unknown 3837 (69) 32,678 (69)”
From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
Bazzichetto, C., Conciatori, F., Luchini, C., Simionato, F., Santoro, R., Vaccaro, V., Corbo, V., Falcone, I., Ferretti, G., Cognetti, F., et al. (2020) · Cells · doi:10.3390/cells9020309 · Cited by 32
“This process has been more recently described also in pancreatic neuroendocrine tumors, and causes fragmentation of a chromosome in many segments with consequent inaccurate reparations [60].”
BackgroundSelf-citationNovel immunotherapy strategies for treatment of neuroendocrine neoplasms
Al‐Toubah, T., Cives, M., & Strosberg, J. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.12.18 · Cited by 33
“The genetic landscape of well-differentiated NETs typically consists of mutations in genes such as MEN1 and DAXX, which are associated with chromatin remodeling (2,3).”
BackgroundTargeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms?
Salvia, A. L., Espinosa-Olarte, P., Martínez, M. C. R., Antón-Pascual, B., & García‐Carbonero, R. (2021) · Cancers · doi:10.3390/cancers13071701 · Cited by 34
Thibodeau, M. L., Stutheit-Zhao, E. Y., Reisle, C., Ch’ng, C., Wong, H., Shen, Y., Jones, M. R., Lim, H. J., Young, S. S., Cremin, C., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a003681 · Cited by 35
“Such signatures, collectively referred to as SBS18/SBS36 signatures, include COSMIC Signature 18, SigProfiler SBS18/SBS36, and SignatureAnalyzer SBS18/SBS36 (Pilati et al. 2017; Scarpa et al. 2017; Viel et al. 2017; Alexandrov et al. 2018).”
Self-citationHeaphy, C. M., & Singhi, A. D. (2022) · Human Pathology · doi:10.1016/j.humpath.2022.07.015 · Cited by 35
Uccella, S. (2024) · Endocrine Pathology · doi:10.1007/s12022-024-09807-2 · Cited by 32
“This is detectable at a molecular level, with the involvement of specific genomic alterations [10, 14, 32, 37, 46], but also non-genomic mechanisms have been invoked, including, but not limited to, the composition of local microbiota [47], the interactions with stromal and inflammatory cells [48],…”
BackgroundInfluentialFolpe, A. L., Tetzlaff, M. T., Billings, S. D., Torres‐Mora, J., Borowsky, A. D., Santiago, T., Ameline, B., & Baumhoer, D. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100537 · Cited by 32
Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors
Bellizzi, A. M. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.11.003 · Cited by 32
Georgeson, P., Harrison, T. A., Pope, B. J., Zaidi, S. H. E., Qu, C., Steinfelder, R. S., Lin, Y., Joo, J. E., Mahmood, K., Clendenning, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30916-1 · Cited by 32
Naeini, M. M., Newell, F., Aoude, L. G., Bonazzi, V., Patel, K., Lampe, G., Koufariotis, L. T., Lakis, V., Addala, V., Kondrashova, O., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38891-x · Cited by 34
“Signature 18, which is associated with MUTYH germline variants 21 , was the dominant signature in a sample (OESO_0119) with a pathogenic somatic variant and loss of heterozygosity in MUTYH (NM_001128425.”
Self-citationManagement of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors
Sonbol, M. B., & Halfdanarson, T. R. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0670-1 · Cited by 30
Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors
Shen, C., Gu, D., Zhou, S., Xu, Y., Sarshekeh, A. M., Halperin, D. M., Shih, Y. T., Yao, J. C., & Dasari, A. N. (2019) · Pancreas · doi:10.1097/mpa.0000000000001431 · Cited by 31
Yan, J., Yu, S., Jia, C., Li, M., & Chen, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188367 · Cited by 33
Kasajima, A., Konukiewitz, B., Schlitter, A. M., Weichert, W., Bräsen, J. H., Agaimy, A., & Klöppel, G. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03156-9 · Cited by 31
Sigel, C., Silva, V. W. K., Reid, M. D., Chhieng, D. C., Baştürk, O., Sigel, K. M., Daniel, T. D., Klimstra, D. S., & Tang, L. H. (2018) · Cancer Cytopathology · doi:10.1002/cncy.21982 · Cited by 31
“001 Large nuclear size 0 (0) 3 (9) 2 (14) .”
Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms
Vandamme, T., Beyens, M., Boons, G., Schepers, A., Kamp, K., Biermann, K., Pauwels, P., de Herder, W. W., Hofland, L. J., Peeters, M., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0120 · Cited by 33
Ji, S., Cao, L., Gao, J., Du, Y., Zeng, Y., Lou, X., Liu, F., Zhang, Y., Xu, J., Shi, X., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.016 · Cited by 32
Self-citationPartelli, S., Andreasi, V., Muffatti, F., Lena, M. S., & Falconi, M. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08425-6 · Cited by 30
Self-citationNeuroendocrine neoplasms of lung, pancreas and gut: a morphology-based comparison
Kasajima, A., & Klöppel, G. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0122 · Cited by 30
Ishida, S., Akita, M., Fujikura, K., Komatsu, M., Sawada, R., Matsumoto, H., Saegusa, J., Itoh, T., Kakeji, Y., & Zen, Y. (2021) · Human Pathology · doi:10.1016/j.humpath.2020.12.008 · Cited by 30
Wang, F., Xu, X., Zeng, Y., Qin, Y., Yu, X., & Ji, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.691557 · Cited by 30
Tsutsui, T., Arakawa, Y., Makino, Y., Kataoka, H., Mineharu, Y., Naito, K., Minamiguchi, S., Hirose, T., Nobusawa, S., Nakano, Y., et al. (2021) · Brain Tumor Pathology · doi:10.1007/s10014-021-00412-3 · Cited by 30
Selective and mechanistic sources of recurrent rearrangements across the cancer genomePreprint
Wala, J. A., Shapira, O., Li, Y., Craft, D., Schumacher, S. E., Imielinski, M. B., Haber, J. E., Roberts, N. D., Yao, X., Stewart, C., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/187609 · Cited by 30
Epigenetic Regulation of Telomere Maintenance for Therapeutic Interventions in Gliomas
Naderlinger, E., & Holzmann, K. (2017) · Genes · doi:10.3390/genes8050145 · Cited by 31
Hidden Markov models lead to higher resolution maps of mutation signature activity in cancer
Huang, X., Sason, I., Wójtowicz, D., Kim, Y.-A., Leiserson, M. D. M., Przytycka, T. M., & Sharan, R. (2019) · Genome Medicine · doi:10.1186/s13073-019-0659-1 · Cited by 27
Update on the Surgical Treatment of Pancreatic Neuroendocrine Tumors
Jeune, F., Taïbi, A., & Gaujoux, S. (2020) · Scandinavian Journal of Surgery · doi:10.1177/1457496919900417 · Cited by 29
“Nat rev Endocrinol 2018;14(11):656–669.”
BackgroundInfluentialp53-PHLDA3-Akt Network: The Key Regulators of Neuroendocrine Tumorigenesis
Chen, Y., & Ohki, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114098 · Cited by 31
“Pancreatic neuroendocrine tumors (PanNETs) are the second most common type of pancreatic epithelial tumor, with an incidence of 2~3 per 100,000 [50].”
BackgroundAdvances in Targeted Therapy and Immunotherapy for Pancreatic Cancer
Liu, X., Li, Z., & Wang, Y. (2021) · Advanced Biology · doi:10.1002/adbi.201900236 · Cited by 29
Luchini, C., Lawlor, R. T., Bersani, S., Vicentini, C., Paolino, G., Mattiolo, P., Pea, A., Cingarlini, S., Milella, M., & Scarpa, A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01096-w · Cited by 29
Self-citationIshida, H., & Lam, A. K.-Y. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103648 · Cited by 29
Sanjaya, P., Maljanen, K., Katainen, R., Waszak, S. M., Ambrose, J. C., Arumugam, P., Bevers, R. P. J., Bleda, M., Boardman-Pretty, F., Boustred, C. R., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01204-4 · Cited by 31
“MUTYH encodes a DNA glycosylase involved in base excision repair, and germline MUTYH mutations have been implicated in a specific G:C>T:A somatic mutation signature found in PanNETs and colorectal cancers [44, 45].”
BackgroundSelf-citationInsights into the biology and treatment strategies of pancreatic neuroendocrine tumors
Buicko, J. L., Finnerty, B. M., Zhang, T., Kim, B. J., Fahey, T. J., & Du, Y. N. (2019) · Annals of Pancreatic Cancer · doi:10.21037/apc.2019.06.02 · Cited by 31
Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment
Tan, B., Zhang, B., & Chen, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1424839 · Cited by 31
Gleeson, F. C., Voss, J. S., Kipp, B. R., Kerr, S. E., Arnam, J. S. V., Mills, J. R., Marcou, C. A., Schneider, A. R., Tu, Z. J., Henry, M. R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18750 · Cited by 28
“[28] If this laboratory technique could be applied to nonoperative cytologic material it would greatly enhance our understanding of pNET tumor biology.”
MethodGenetic and epigenetic alterations in pancreatic neuroendocrine tumors
Tirosh, A., & Kebebew, E. (2020) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2020.03.11 · Cited by 28
“A comprehensive genomic analysis of PNETs using whole-genome sequencing was published by Scarpa and colleagues (4).”
BackgroundMethodInfluentialTirosh, A., Killian, J., Petersen, D., Zhu, Y., Walker, R., Blau, J., Nilubol, N., Patel, D., Agarwal, S., Weinstein, L., et al. (2020) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/clinem/dgaa477 · Cited by 25
Changing biological behaviour of NETs during the evolution of the disease: progress on progression
Alexandraki, K., Spyroglou, A., Kykalos, S., Daskalakis, K., Kyriakopoulos, G., Sotiropoulos, G. C., Kaltsas, G., & Grossman, A. B. (2021) · Endocrine Related Cancer · doi:10.1530/erc-20-0473 · Cited by 29
Ramarao-Milne, P., Kondrashova, O., Patch, A., Nones, K., Koufariotis, L. T., Newell, F., Addala, V., Lakis, V., Holmes, O., Leonard, C., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100540 · Cited by 29
Self-citationAgaimy, A., Kasajima, A., Stoehr, R., Haller, F., Schubart, C., Tögel, L., Pfarr, N., von Werder, A., Pavel, M., Sessa, F., et al. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03484-4 · Cited by 28
Rivero, J. D., Gangi, A., Annes, J. P., Jasim, S., Keller, J., Lundholm, M. D., Silverstein, J. M., Vaghaiwalla, T. M., & Wermers, R. A. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.02.001 · Cited by 28
Pancreatic Neuroendocrine Neoplasm Associated with a Familial MAX Deletion
Petignot, S., Daly, A., Castermans, E., Korpershoek, E., Scagnol, I., Beckers, P., Dideberg, V., Rohmer, V., Bours, V., & Beckers, A. M. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1186-0790 · Cited by 27
Boons, G., Vandamme, T., Ibrahim, J., Roeyen, G., Driessen, A. L. C., Peeters, D. J. E., Lawrence, B. J., Print, C. G., Peeters, M., Camp, G. V., et al. (2020) · Cancers · doi:10.3390/cancers12061461 · Cited by 29
“Gene set enrichment analysis has highlighted the MAPK pathway as a possibly important pathway in PNENs, which has been suggested before based on genetic and epigenetic alterations [9,12,32,33].”
BackgroundInfluentialMolecular alterations in pancreatic tumors
Visani, M., Acquaviva, G., Leo, A. D., Sanza, V., Merlo, L., Maloberti, T., Brandes, A. A., Franceschi, E., Battista, M. D., Masetti, M., et al. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i21.2710 · Cited by 29
Huang, X., Huang, K., Johnson, T. S., Radovich, M., Zhang, J., Ma, J., & Wang, Y. (2021) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqab097 · Cited by 26
“For each GO term, we did survival analysis on samples with the term mutated and samples with the term unmutated using PAAD samples (45,49–56).”
MethodCdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors
Carter, A. M., Kumar, N., Herring, B., Tan, C., Guenter, R. E., Telange, R., Howse, W., Viol, F., McCaw, T. R., Bickerton, H. H., et al. (2021) · Oncogenesis · doi:10.1038/s41389-021-00372-5 · Cited by 27
“This finding prompted a full comparison with sequencing datasets from human PanNETs, which revealed that 48 genes with mutations in coding regions in INS-p25OE tumors are also mutated in a published set of 98 human PanNETs [42] (Fig.”
ResultCanakis, A., & Lee, L. S. (2022) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v14.i5.267 · Cited by 27
Padi, S. K. R., Singh, N., Bearss, J. J., Olive, V., Song, J. H., Cardó‐Vila, M., Kraft, A. S., & Okumura, K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904774116 · Cited by 30
Sandini, M., Strobel, O., Hank, T. P., Lewosinska, M., Nießen, A., Hackert, T., Büchler, M. W., & Schimmack, S. J. (2019) · Surgery · doi:10.1016/j.surg.2019.11.007 · Cited by 27
Prognostic relevance of proliferation-related miRNAs in pancreatic neuroendocrine neoplasms
Grolmusz, V. K., Kövesdi, A., Borka, K., Igaz, P., & Patócs, A. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0305 · Cited by 26
Clinical genetic testing in endocrinology: Current concepts and contemporary challenges
Newey, P. J. (2019) · Clinical Endocrinology · doi:10.1111/cen.14053 · Cited by 29
Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool
Hackeng, W., Dreijerink, K., de Leng, W. D., Morsink, F., Valk, G., Vriens, M., Offerhaus, G., Geisenberger, C., & Brosens, L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3281 · Cited by 20
Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades
Simbolo, M., Bilotta, M., Mafficini, A., Luchini, C., Furlan, D., Inzani, F. S., Petrone, G., Bonvissuto, D., Rosa, S. L., Schinzari, G., et al. (2021) · Cancers · doi:10.3390/cancers13092054 · Cited by 26
“This subgroup later resulted to be associated with hypoxia-induced genes and extensive dysregulated expression of immune-related genes, but no further relationship between tumor grade and expression profiles emerged [4,18].”
BackgroundInfluentialSelf-citationMastrosimini, M. G., Manfrin, E., Remo, A., Bellis, M. D., Parisi, A., Pedron, S., Luchini, C., Brunelli, M., Ammendola, S., Bernardoni, L., et al. (2023) · Pancreatology · doi:10.1016/j.pan.2023.05.002 · Cited by 26
Self-citationBucau, M., Laurent-Bellue, A., Poté, N., Hentic, O., Cros, J. F., Mikaïl, N., Rebours, V., Ruszniewski, P. B., Lebtahi, R., & Couvelard, A. (2017) · Neuroendocrinology · doi:10.1159/000480239 · Cited by 26
MENIN loss as a tissue-specific driver of tumorigenesis
Li, J. W. Y., Hua, X., Reidy‐Lagunes, D. L., & Untch, B. R. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.09.032 · Cited by 26
Pivovarčíková, K., Agaimy, A., Martínek, P., Alaghehbandan, R., Pérez‐Montiel, D., Alvarado‐Cabrero, I., Rogala, J., Kuroda, N., Rychlý, B., Gašparov, S., et al. (2019) · Histopathology · doi:10.1111/his.13856 · Cited by 26
“Furthermore, recurring features have been reported, such as inactivation of MEN1, VHL, and TSC1/2, hyperactivation of the PI3K–mTOR pathway and inactivation of ATRX/DAXX in a proportion of PanNET cases.(67,68) Another group of NETs studied with molecular–genetic techniques were lung carcinoids (typical carcinoid and a…”
BackgroundCapodanno, Y., Altieri, B., Elders, R., Colao, A., Faggiano, A., & Schrader, J. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101269 · Cited by 26
“On this note, it has been recently hypothesized by Yu et al. that malignant INS could be derived in most cases from non-functional PNETs [84].”
BackgroundInfluentialRao, M., Oh, K., Moffitt, R. A., Thompson, P. A., Li, J., Liu, J., Sasson, A. R., Georgakis, G., Kim, J., Choi, M., et al. (2020) · Molecular Case Studies · doi:10.1101/mcs.a004978 · Cited by 26
“They are generally well-differentiated with a lack of significant mutations in major driver genes such as TP53 , RB1 , KRAS , and PTEN (Scarpa et al. 2017; Simbolo et al. 2018).”
Understanding the increasing incidence of neuroendocrine tumors
Pathak, S., Starr, J. S., Halfdanarson, T. R., & Sonbol, M. B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2237593 · Cited by 25
“Aberrations affecting hypoxia and hypoxia-inducible factor (HIF) signaling were found as well [55].”
InfluentialZeng, Y., Li, Q., Hu, Y., Hu, H., Xu, J., Guo, M., Zhang, W., Lou, X., Wang, Y., Gao, H., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216769 · Cited by 26
Update in the management of gastroenteropancreatic neuroendocrine tumors
Sedlack, A. J. H., Varghese, D. G., Naimian, A., Anari, P. Y., Bodei, L., Hallet, J. I., Riechelmann, R. P., Halfdanarson, T., Capdevilla, J., & Rivero, J. D. (2024) · Cancer · doi:10.1002/cncr.35463 · Cited by 25
Modeling double strand break susceptibility to interrogate structural variation in cancer
Ballinger, T. J., Bouwman, B. A. M., Mirzazadeh, R., Garnerone, S., Crosetto, N., & Semple, C. A. M. (2019) · Genome biology · doi:10.1186/s13059-019-1635-1 · Cited by 22
Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms
Pozas, J., Román, M. S., Alonso‐Gordoa, T., Pozas, M., Caracuel, L., Carrato, A., & Molina‐Cerrillo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194949 · Cited by 25
“Four molecular pathways were found to be involved in the development of these tumors [27]: (1) DNA damage repair: Germline mutations seem to have an important role in the development of P-NETs; several germline-damaging variants of the base-excision-repair MUTYH gene and the homologous recombination genes BRCA2 and CH…”
BackgroundSoft‐tissue sarcoma with MN1‐BEND2 fusion: A case report and comparison with astroblastoma
Yoshida, A., Satomi, K., Kobayashi, E., Ryo, E., Matsushita, Y., Narita, Y., Ichimura, K., Kawai, A., & Mori, T. (2022) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23028 · Cited by 25
Meier, M., Nuciforo, S., Coto‐Llerena, M., Gallon, J., Matter, M. S., Ercan, C., Vosbeck, J., Terracciano, L., Soysal, S. D., Boll, D. T., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00150-3 · Cited by 25
Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation
Shen, X., Wang, X., Lu, X., Zhao, Y., & Guan, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.967071 · Cited by 24
The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms
Liu, M., Li, N., Tang, H., Chen, L., Liu, X., Wang, Y., Lin, Y., Luo, Y., Wei, S., Wen, W., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad093 · Cited by 25
Persani, L., de Filippis, T., Colombo, C., & Gentilini, D. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0379 · Cited by 28
Cao, Y., Ma, Y., Yu, J., Sun, Y. L., Sun, T., Shao, Y. W., Li, J., Shen, L., & Lu, M. S. (2020) · 癌症：英文版 · doi:10.1002/cac2.12114 · Cited by 25
“NGS analysis contributed to the pathogenic diagnosis of this case, as we identified an inactivating germline mutation in the base-excision-repair gene MUTYH which was reported as a novel pathogenesis in PanNETs [14].”
BackgroundInfluentialVarghese, D. G., Rivero, J. D., & Bergsland, E. K. (2023) · Cancers · doi:10.3390/cancers15143712 · Cited by 24
“Recurrent genomic alterations are uncommon in gastrointestinal NETs, but pancreatic NETs are characterized by alterations in MEN1, DAXX/ATRX, and mTOR pathway genes [10,12].”
BackgroundEpidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms
Uhlig, J., Nie, J., Gibson, J. A., Cecchini, M., Stein, S., Lacy, J., Kunz, P. L., & Kim, H. S. (2024) · Scientific Reports · doi:10.1038/s41598-024-81518-4 · Cited by 24
Cyto-histology in NET: what is necessary today and what is the future?
Inzani, F. S., Petrone, G., Fadda, G., & Rindi, G. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9428-x · Cited by 24
Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions
Detjen, K. M., Hammerich, L., Özdirik, B., Demir, M., Wiedenmann, B., Tacke, F., Jann, H., & Roderburg, C. (2020) · Neuroendocrinology · doi:10.1159/000509864 · Cited by 23
Miki, M., Oono, T., Fujimori, N., Takaoka, T., Kawabe, K., Miyasaka, Y., Ohtsuka, T., Saito, D., Nakamura, M., Ohkawa, Y., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2232 · Cited by 24
von Arx, C., Capozzi, M., López-Jiménez, E., Ottaiano, A., Tatangelo, F., Di Mauro, A., Nasti, G., Tornesello, M. L., & Tafuto, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091277 · Cited by 24
“Previously GEP-NENs were considered as a unique group of tumours, however, currently, many studies have highlighted the biological and molecular differences between pancreatic and GI NENs, as well as between the GI NENs originating from different organs of the GI tract [11,15,16,18].”
BackgroundInfluentialPellat, A., Cottereau, A., Palmieri, L., Soyer, P. A., Marchèse, U., Brézault, C., & Coriat, R. (2021) · Cancers · doi:10.3390/cancers13102448 · Cited by 22
“Conversely, inactivating mutations in DAXX and ATRX and in MEN1 are found exclusively in PanNET [68,70,71].”
BackgroundMining mutation contexts across the cancer genome to map tumor site of origin
Chakraborty, S., Martin, A. S., Guan, Z., Begg, C. B., & Shen, R. (2021) · Nature Communications · doi:10.1038/s41467-021-23094-z · Cited by 22
Targeting HDACs in Pancreatic Neuroendocrine Tumor Models
Schmitz, R. L., Weißbach, J., Kleilein, J., Bell, J. L., Hüttelmaier, S., Viol, F., Clauditz, T. S., Grabowski, P., Laumen, H., Rosendahl, J., et al. (2021) · Cells · doi:10.3390/cells10061408 · Cited by 23
“Recent genome-wide sequence analyses in pancreatic NET (PanNET) have uncovered a large number of mutated genes involved in epigenetic modulation [6,7].”
BackgroundInfluentialEZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs)
April-Monn, S., Andreasi, V., Lena, M. S., Sadowski, M. C., Kim‐Fuchs, C., Buri, M. C., Ketkar, A., Maire, R., Domenico, A. D., Schrader, J., et al. (2021) · Cancers · doi:10.3390/cancers13195014 · Cited by 23
“Well-differentiated G1 and G2 PanNETs present mutations in MEN1, DAXX, and ATRX in almost 40% of patients, while 15% carry mutations in genes encoding members of the mTOR pathway [4,5].”
BackgroundMethodSelf-citationBean, G. R., Najjar, S. N., Shin, S. J., Hosfield, E. M., Caswell-Jin, J. L., Urisman, A., Jones, K. D., Chen, Y., & Krings, G. (2022) · Modern Pathology · doi:10.1038/s41379-022-01090-y · Cited by 24
Depoilly, T., Leroux, R., Andrade, D. C., Nicolle, R., Burgio, M. D., Marinoni, I., Dokmak, S., Ruszniewski, P. B., Hentic, O., Paradis, V., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01110-x · Cited by 23
Pedraza‐Arévalo, S., Alors‐Pérez, E., Blázquez‐Encinas, R., Herrera-Martínez, A. D., Jiménez‐Vacas, J. M., Fuentes-Fayos, A. C., Reyes, Ó., Ventura, S., Sánchez‐Sánchez, R., Ortega-Salas, R. M., et al. (2022) · Translational research · doi:10.1016/j.trsl.2022.07.005 · Cited by 21
Battistella, A., Partelli, S., Andreasi, V., Marinoni, I., Palumbo, D., Tacelli, M., Lena, M. S., Muffatti, F., Mushtaq, J., Capurso, G., et al. (2022) · Surgery · doi:10.1016/j.surg.2022.06.017 · Cited by 23
Self-citationPusceddu, S., Barretta, F., Trama, A., Botta, L., Milione, M., Buzzoni, R., de Braud, F., Mazzaferro, V., Pastorino, U., Seregni, E. C., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0489 · Cited by 23
Self-citationMolecular Genetic Studies of Pancreatic Neuroendocrine Tumors
Stevenson, M., Lines, K. E., & Thakker, R. V. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.04.007 · Cited by 23
Arakelyan, J., Zohrabyan, D., & Philip, P. A. (2020) · Cancer · doi:10.1002/cncr.33354 · Cited by 23
“However, germline mutations (eg, MUTYH) may also be seen in patients with sporadic panNETs based on recent reports.(6)”
BackgroundGrande, E., Rodríguez‐Antona, C., López, C., Alonso‐Gordoa, T., Benavent, M., Capdevila, J., Teulé, À., Custodio, A., Sevilla, I., Hernando, J., et al. (2021) · The Oncologist · doi:10.1002/onco.13885 · Cited by 23
Lou, X., Zeng, Y., Xu, X., Jiang, M., Lu, R., Jing, D., Zhang, W., Gao, H., Wang, F., Zhang, Y., et al. (2022) · Human Cell · doi:10.1007/s13577-022-00696-3 · Cited by 23
A combined bovine herpesvirus 1 gB-gD DNA vaccine induces immune response in mice
Caselli, E., Boni, M., Luca, D. D., Salvatori, D. C. F., Vita, A., & Cassai, E. (2004) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2004.10.001 · Cited by 23
Chronische Darmerkrankungen beim Hund: Eine Übersicht
Allenspach, K., & Gaschen, F. P. (2003) · Schweizer Archiv für Tierheilkunde · doi:10.1024/0036-7281.145.5.209 · Cited by 23
Liu, Y., Han, G., Feng, K., Lin, X., Zhong, W., Liu, Y., Wang, C., Zhang, C., & Liu, X. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.043 · Cited by 25
The future: surgical advances in MEN1 therapeutic approaches and management strategies
Sadowski, S. M., Cadiot, G., Dansin, É., Goudet, P., & Triponez, F. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0285 · Cited by 22
Smith, D. K., Kates, L., Durinck, S., Patel, N. A., Stawiski, E. W., Kljavin, N. M., Foreman, O., Sipos, B., Solloway, M. J., Allan, B. B., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100058 · Cited by 22
Metadata
- Authors
- Initiative, A. P. C. G., Scarpa, A., Chang, D. K., Nones, K., Corbo, V., Patch, A.-M., Bailey, P., Lawlor, R. T., Johns, A. L., Miller, D. K., Mafficini, A., Rusev, B., Scardoni, M., Antonello, D., Barbi, S., Sikora, K. O., Cingarlini, S., Vicentini, C., McKay, S., Quinn, M. C. J., Bruxner, T. J. C., Christ, A. N., Harliwong, I., Idrisoglu, S., McLean, S., Nourse, C., Nourbakhsh, E., Wilson, P. J., Anderson, M. J., Fink, J. L., Newell, F., Waddell, N., Holmes, O., Kazakoff, S. H., Leonard, C., Wood, S., Xu, Q., Nagaraj, S. H., Amato, E., Dalai, I., Bersani, S., Cataldo, I., Dei Tos, A. P., Capelli, P., Davì, M. V., Landoni, L., Malpaga, A., Miotto, M., Whitehall, V. L. J., Leggett, B. A., Harris, J. L., Harris, J., Jones, M. D., Humphris, J., Chantrill, L. A., Chin, V., Nagrial, A. M., Pajic, M., Scarlett, C. J., Pinho, A., Rooman, I., Toon, C., Wu, J., Pinese, M., Cowley, M., Barbour, A., Mawson, A., Humphrey, E. S., Colvin, E. K., Chou, A., Lovell, J. A., Jamieson, N. B., Duthie, F., Gingras, M.-C., Fisher, W. E., Dagg, R. A., Lau, L. M. S., Lee, M., Pickett, H. A., Reddel, R. R., Samra, J. S., Kench, J. G., Merrett, N. D., Epari, K., Nguyen, N. Q., Zeps, N., Falconi, M., Simbolo, M., Butturini, G., Van Buren, G., Partelli, S., Fassan, M., Khanna, K. K., Gill, A. J., Wheeler, D. A., Gibbs, R. A., Musgrove, E. A., Bassi, C., Tortora, G., Pederzoli, P., Pearson, J. V., Waddell, N., Biankin, A. V., & Grimmond, S. M.
- Affiliations
- University of Verona (IT)
- Garvan Institute of Medical Research (AU)
- The University of Queensland (AU)
- Queensland University of Technology (AU)
- Glasgow Royal Infirmary (GB)
- Baylor College of Medicine (US)
- Children's Hospital at Westmead (AU)
- The University of Sydney (AU)
- Fremantle Hospital (AU)
- Royal Adelaide Hospital (AU)
- The University of Melbourne (AU)
- Corresponding author
- Scarpa, Aldo
- Biankin, Andrew V.
- Grimmond, Sean M.
- ORCID
- Scarpa, Aldo
- Chang, David K.
- Corbo, Vincenzo
- Patch, Ann-Marie
- Bailey, Peter
- Lawlor, Rita T.
- Johns, Amber L.
- Mafficini, Andrea
- Rusev, Borislav
- Antonello, Davide
- Barbi, Stefano
- Cingarlini, Sara
- Vicentini, Caterina
- Quinn, Michael C. J.
- Bruxner, Timothy J. C.
- Christ, Angelika N.
- Harliwong, Ivon
- Nourbakhsh, Ehsan
- Wilson, Peter J.
- Anderson, Matthew J.
- Fink, J. Lynn
- Newell, Felicity
- Holmes, Oliver
- Kazakoff, Stephen H.
- Leonard, Conrad
- Wood, Scott
- Nagaraj, Shivashankar Hiriyur
- Bersani, Samantha
- Cataldo, Ivana
- Davì, Maria Vittoria
- Landoni, Luca
- Malpaga, Anna
- Miotto, Marco
- Whitehall, Vicki L. J.
- Leggett, Barbara A.
- Harris, Jonathan
- Jones, Marc D.
- Chantrill, Lorraine A.
- Chin, Venessa
- Nagrial, Adnan M.
- Pajic, Marina
- Scarlett, Christopher J.
- Pinho, Andreia
- Rooman, Ilse
- Toon, Christopher
- Wu, Jianmin
- Pinese, Mark
- Cowley, Mark
- Barbour, Andrew
- Mawson, Amanda
- Colvin, Emily K.
- Chou, Angela
- Jamieson, Nigel B.
- Gingras, Marie-Claude
- Dagg, Rebecca A.
- Lau, Loretta M. S.
- Lee, Michael
- Pickett, Hilda A.
- Reddel, Roger R.
- Samra, Jaswinder S.
- Kench, James G.
- Merrett, Neil D.
- Nguyen, Nam Q.
- Zeps, Nikolajs
- Falconi, Massimo
- Simbolo, Michele
- Partelli, Stefano
- Fassan, Matteo
- Khanna, Kum Kum
- Gill, Anthony J.
- Wheeler, David A.
- Gibbs, Richard A.
- Bassi, Claudio
- Tortora, Giampaolo
- Pearson, John V.
- Waddell, Nicola
- Biankin, Andrew V.
- Grimmond, Sean M.
- Venue
- Nature
- Published
- 2017-02-15
- Volume
- 543
- Issue
- 7643
- Pages
- 65-71
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2589112207
- Cited by
- 999
- References
- 62
- Citations by year
- 2026: 65 · 2025: 101 · 2024: 103 · 2023: 110 · 2022: 126 · 2021: 108 · 2020: 131 · 2019: 89 · 2018: 103 · 2017: 52
- FWCI
- 81.15
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-09-27)
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson, FLF2015_04_GLASGOW)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (23526, 17263, 22533)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Medical Research Council (MR/N005813/1)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic neuroendocrine tumors, mutational signatures, MUTYH, germline mutations, CHEK2, BRCA2, MEN1, VHL, chromatin remodeling, DNA repair, mTOR signaling, telomere maintenance, hypoxia, carcinogenesis
- MeSH terms
- Base Sequence, Calmodulin-Binding Proteins, Chromosome Aberrations, DNA Mutational Analysis, DNA Repair, Female, Humans, Male, Pancreatic Neoplasms, Genome, Human, RNA-Binding Proteins, Telomere, Germ-Line Mutation, Carcinoma, Neuroendocrine, Genomics, RNA-Binding Protein EWS, Chromatin Assembly and Disassembly, DNA Glycosylases, DNA Copy Number Variations, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
